Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2025 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
September 08, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx appoints Adam Mostafa as Chief Financial Officer

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK...
August 19, 2025 10:59 ET | Source: Spherix Global Insights

Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...
July 23, 2025 04:08 ET | Source: Research and Markets

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The atopic dermatitis market...
June 26, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with AD
June 10, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

The first child has been enrolled in Phase 2 INTEGUMENT-INFANT study evaluating the safety and tolerability of investigational ZORYVE cream for AD
June 07, 2025 18:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more...
June 06, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Arcutis to present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, taking place in Nashville, TN, from June 6-7, 2025.
May 26, 2025 10:53 ET | Source: Research and Markets

Prurigo Nodularis Market - Global and Regional Analysis and Forecasts 2025-2035 | Advancements in Biologic Therapies Revolutionize Prurigo Nodularis Treatment

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Prurigo Nodularis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...
May 20, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight

New York, USA, May 20, 2025 (GLOBE NEWSWIRE) -- Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The moderate to severe atopic dermatitis...